Story perspectives

Capricor Stock Soars 341% After Promising DMD Trial Results

12/4/2025

Summary

Story summary

Capricor Therapeutics' stock jumped 341% to $28.05 after Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy (DMD).
HOPE-3 trial enrolled 106 participants and showed a 54% reduction in disease progression and 91% improvement in cardiac function.
Cardiologists emphasized the importance of these findings for cardiac stabilization in DMD.
Capricor plans to use the data to address U.S. Food and Drug Administration (FDA) concerns and seek approval, despite skepticism.

History

Historical Context

In 2017, the FDA's approval of Exondys 51 marked a significant advancement in Duchenne muscular dystrophy (DMD) treatment, following decades of limited options. The HOPE-3 trial demonstrated a 54% reduction in disease progression among 106 participants, reflecting a broader trend toward innovative therapies for DMD. This progress highlights the ongoing commitment to improving patient outcomes in this challenging condition.

1 of 2

Story summary

Capricor Therapeutics' stock jumped 341% to $28.05 after Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy (DMD).
HOPE-3 trial enrolled 106 participants and showed a 54% reduction in disease progression and 91% improvement in cardiac function.
Cardiologists emphasized the importance of these findings for cardiac stabilization in DMD.
Capricor plans to use the data to address U.S. Food and Drug Administration (FDA) concerns and seek approval, despite skepticism.

1 / 2